Search

Your search keyword '"Andritsos, Leslie"' showing total 839 results
Start Over Author "Andritsos, Leslie"
839 results on '"Andritsos, Leslie"'

1. Hairy cell leukemia variant and WHO classification correspondence Re: 5th edition WHO classification haematolymphoid tumors: lymphoid neoplasms

Author

Grever, Michael, Andritsos, Leslie, Anghelina, Mirela, Arons, Evgeny, Banerji, Versha, Barrientos, Jacqueline, Bhat, Seema A., Blachly, James, Broccoli, Alessandro, Call, Timothy, Dearden, Claire, Dietrich, Sascha, Else, Monica, Epperla, Narendranath, Fagarasanu, Andrei, Falini, Brunangelo, Forconi, Francesco, Gozzetti, Alessandro, Hampel, Paul, Hermel, David J., Iyengar, Sunil, Johnston, James B., Juliusson, Gunnar, Kreitman, Robert J., Lauria, Francesco, Lozanski, Gerard, Oakes, Christopher C., Parikh, Sameer A., Park, Jae, Quest, Graeme, Rai, Kanti, Ravandi, Farhad, Robak, Tadeusz, Rogers, Kerry A., Saven, Alan, Seymour, John F., Tadmor, Tamar, Tallman, Martin S., Tam, Constantine S., Tiacci, Enrico, Troussard, Xavier, Wörmann, Bernhard, Zent, Clive S., Zenz, Thorsten, and Zinzani, Pier Luigi

Published
2024
Full Text
View/download PDF

3. Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)–an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT)

Author

Kansagra, Ankit J, Frey, Noelle V, Bar, Merav, Laetsch, Theodore W, Carpenter, Paul A, Savani, Bipin N, Heslop, Helen E, Bollard, Catherine M, Komanduri, Krishna V, Gastineau, Dennis A, Chabannon, Christian, Perales, Miguel A, Hudecek, Michael, Aljurf, Mahmoud, Andritsos, Leslie, Barrett, John A, Bachanova, Veronika, Bonini, Chiara, Ghobadi, Armin, Gill, Saar I, Hill, Joshua A, Kenderian, Saad, Kebriaei, Partow, Nagler, Arnon, Maloney, David, Liu, Hien D, Shah, Nirali N, Kharfan-Dabaja, Mohamed A, Shpall, Elizabeth J, Mufti, Ghulam J, Johnston, Laura, Jacoby, Elad, Bazarbachi, Ali, DiPersio, John F, Pavletic, Steven Z, Porter, David L, Grupp, Stephan A, Sadelain, Michel, Litzow, Mark R, Mohty, Mohamad, and Hashmi, Shahrukh K

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Cancer, Pediatric, Childhood Leukemia, Immunization, Genetics, Transplantation, Biotechnology, Gene Therapy, Pediatric Cancer, Pediatric Research Initiative, Hematology, Orphan Drug, Rare Diseases, Development of treatments and therapeutic interventions, 5.2 Cellular and gene therapies, Good Health and Well Being, Clinical Sciences, Cardiovascular medicine and haematology, Oncology and carcinogenesis
Abstract

On August 30, 2017, the U.S. Food and Drug Administration (US-FDA) approved tisagenlecleucel (KYMRIAH, Novartis, Basel, Switzerland), a synthetic bioimmune product of anti-CD19 chimeric antigen receptor-T cells (CAR-T), for the treatment of children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). With this new era of personalized cancer immunotherapy, multiple challenges are present ranging from implementation of a CAR-T program to safe delivery of the drug, long-term toxicity monitoring and disease assessments. To address these issues, experts representing the American Society for Blood and Marrow Transplant (ASBMT), the European Group for Blood and Marrow Transplantation (EBMT), the International Society of Cell and Gene Therapy (ISCT), and the Foundation for the Accreditation of Cellular Therapy (FACT), formed a global CAR-T task force to identify and address key questions pertinent for hematologists and transplant physicians regarding the clinical use of anti CD19 CAR-T therapy in patients with B-ALL. This article presents an initial roadmap for navigating common clinical practice scenarios that will become more prevalent now that the first commercially available CAR-T product for B-ALL has been approved.

Published
2019

4. Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Transplantation and Cellular Therapy

Author

Kansagra, Ankit J, Frey, Noelle V, Bar, Merav, Laetsch, Theodore W, Carpenter, Paul A, Savani, Bipin N, Heslop, Helen E, Bollard, Catherine M, Komanduri, Krishna V, Gastineau, Dennis A, Chabannon, Christian, Perales, Miguel A, Hudecek, Michael, Aljurf, Mahmoud, Andritsos, Leslie, Barrett, John A, Bachanova, Veronika, Bonini, Chiara, Ghobadi, Armin, Gill, Saar I, Hill, Joshua, Kenderian, Saad, Kebriaei, Partow, Nagler, Arnon, Maloney, David, Liu, Hien D, Shah, Nirali N, Kharfan-Dabaja, Mohamed A, Shpall, Elizabeth J, Mufti, Ghulam J, Johnston, Laura, Jacoby, Elad, Bazarbachi, Ali, DiPersio, John F, Pavletic, Steven Z, Porter, David L, Grupp, Stephan A, Sadelain, Michel, Litzow, Mark R, Mohty, Mohamad, and Hashmi, Shahrukh K

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Transplantation, Childhood Leukemia, Pediatric Cancer, Pediatric, Biotechnology, Orphan Drug, Genetics, Pediatric Research Initiative, Cancer, Rare Diseases, Gene Therapy, Immunization, Hematology, Development of treatments and therapeutic interventions, 5.2 Cellular and gene therapies, Good Health and Well Being, Antigens, CD19, Child, Critical Pathways, Drug Approval, Expert Testimony, Humans, Immunotherapy, Adoptive, Practice Patterns, Physicians', Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Receptors, Antigen, T-Cell, Societies, Medical, United States, Young Adult, Chimeric antigen receptor, Leukemia, T cell, Clinical Sciences, Cardiovascular medicine and haematology
Abstract

On August 30, 2017 the US Food and Drug Administration approved tisagenlecleucel (Kymriah; Novartis, Basel, Switzerland), a synthetic bioimmune product of anti-CD19 chimeric antigen receptor T cells (CAR-T), for the treatment of children and young adults with relapsed/refractory B cell acute lymphoblastic leukemia (B-ALL). With this new era of personalized cancer immunotherapy, multiple challenges are present, ranging from implementation of a CAR-T program to safe delivery of the drug, long-term toxicity monitoring, and disease assessments. To address these issues experts representing the American Society for Blood and Marrow Transplant, the European Society for Blood and Marrow Transplantation, the International Society of Cell and Gene Therapy, and the Foundation for the Accreditation of Cellular Therapy formed a global CAR-T task force to identify and address key questions pertinent for hematologists and transplant physicians regarding the clinical use of anti CD19 CAR-T therapy in patients with B-ALL. This article presents an initial roadmap for navigating common clinical practice scenarios that will become more prevalent now that the first commercially available CAR-T product for B-ALL has been approved.

Published
2019

5. Patient-driven research: Initial results from a prospective health–related quality of life study performed at the request of patients living with hairy cell leukemia

Author

Anghelina, Mirela, Naughton, Michelle J., Zhao, Qiuhong, Ruppert, Amy S., Neal, Jasmine, Rogers, Kerry A., Blachly, James S., Lozanski, Gerard, Bhat, Seema A., Kraut, Eric, Epperla, Narendranath, Mathur, Puneet, Zent, Clive S., Banerji, Versha, Dearden, Claire, Hutchinson, Terri, Grever, Michael, and Andritsos, Leslie A.

Published
2022
Full Text
View/download PDF

6. Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia

Author

Ravandi, Farhad, Kreitman, Robert J., Tiacci, Enrico, Andritsos, Leslie, Banerji, Versha, Barrientos, Jacqueline C., Bhat, Seema A., Blachly, James S., Broccoli, Alessandro, Call, Timothy, Chihara, Dai, Dearden, Claire, Demeter, Judit, Dietrich, Sasha, Else, Monica, Epperla, Narendranath, Falini, Brunangelo, Forconi, Francesco, Gladstone, Douglas E., Gozzetti, Alessandro, Iyengar, Sunil, Johnston, James B., Jorgensen, Jeffrey, Juliusson, Gunnar, Lauria, Francesco, Lozanski, Gerard, Parikh, Sameer A., Park, Jae H., Polliack, Aaron, Quest, Graeme, Robak, Tadeusz, Rogers, Kerry A., Saven, Alan, Seymour, John F., Tadmor, Tamar, Tallman, Martin S., Tam, Constantine S., Thompson, Philip A., Troussard, Xavier, Zent, Clive S., Zenz, Thorsten, Zinzani, Pier Luigi, Wörmann, Bernhard, Rai, Kanti, and Grever, Michael

Published
2022
Full Text
View/download PDF

7. Hairy cell leukemia and COVID-19 adaptation of treatment guidelines

Author

Grever, Michael, Andritsos, Leslie, Banerji, Versha, Barrientos, Jacqueline C., Bhat, Seema, Blachly, James S., Call, Timothy, Cross, Matthew, Dearden, Claire, Demeter, Judit, Dietrich, Sasha, Falini, Brunangelo, Forconi, Francesco, Gladstone, Douglas E., Gozzetti, Alessandro, Iyengar, Sunil, Johnston, James B., Juliusson, Gunnar, Kraut, Eric, Kreitman, Robert J., Lauria, Francesco, Lozanski, Gerard, Parikh, Sameer A., Park, Jae, Polliack, Aaron, Ravandi, Farhad, Robak, Tadeusz, Rogers, Kerry A., Saven, Alan, Seymour, John F., Tadmor, Tamar, Tallman, Martin S., Tam, Constantine S., Tiacci, Enrico, Troussard, Xavier, Zent, Clive, Zenz, Thorsten, Zinzani, Pier Luigi, and Wörmann, Bernhard

Published
2021
Full Text
View/download PDF

9. Externally validated predictive clinical model for untreated del(17p13.1) chronic lymphocytic leukemia patients

Author

Stephens, Deborah M, Ruppert, Amy S, Weirda, William G, Jones, Jeffrey A, Woyach, Jennifer A, Maddocks, Kami, Jaglowski, Samantha M, Andritsos, Leslie A, Flynn, Joseph M, Grever, Michael R, Lozanski, Gerard, Tam, Constantine, O'Brien, Susan, Keating, Michael J, Muthusamy, Natarajan, Abruzzo, Lynne V, Heerema, Nyla A, and Byrd, John C

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Prevention, Clinical Research, Cancer, Hematology, Lymphoma, Rare Diseases, Detection, screening and diagnosis, 4.1 Discovery and preclinical testing of markers and technologies, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Base Sequence, Chromosomes, Human, Pair 17, Female, Humans, Karyotype, Leukemia, Lymphocytic, Chronic, B-Cell, Male, Middle Aged, Molecular Sequence Data, Prognosis, Proportional Hazards Models, Retrospective Studies, Risk, Sequence Deletion, Survival Analysis, Cardiorespiratory Medicine and Haematology, Immunology, Cardiovascular medicine and haematology
Abstract

Little is known about outcomes of patients with chronic lymphocytic leukemia (CLL) with del(17p13.1) karyotype at diagnosis. We reviewed 114 de novo del(17p13.1) CLL patients seen at our institution. Using proportional hazards models to identify pretreatment clinical variables significantly associated with treatment-free survival (TFS) and overall survival (OS), we developed a simplified risk score for de novo del(17p13.1) CLL patients to predict TFS and OS based on these variables. These scores, particularly the very highest, can be utilized to identify high-risk patients for expedient enrollment on clinical trials. Our data support careful observation for low-risk patients, potentially preventing unnecessary use of aggressive therapies.

Published
2015

11. Final results of EFC6663: A multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia

Author

Lanasa, Mark C, Andritsos, Leslie, Brown, Jennifer R, Gabrilove, Janice, Caligaris-Cappio, Federico, Ghia, Paolo, Larson, Richard A, Kipps, Thomas J, Leblond, Veronique, Milligan, Donald W, Janssens, Ann, Johnson, Amy J, Heerema, Nyla A, Bühler, Andreas, Stilgenbauer, Stephan, Devin, Jeanne, Hallek, Michael, Byrd, John C, and Grever, Michael R

Subjects
Rare Diseases, Cancer, Clinical Trials and Supportive Activities, Patient Safety, Lymphoma, Hematology, Clinical Research, Pediatric, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Female, Flavonoids, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Male, Middle Aged, Piperidines, Recurrence, Survival Analysis, Treatment Failure, Vidarabine, Chronic lymphocytic leukemia, Flavopiridol, Therapy, Tumor lysis syndrome, Cyclin dependent kinase inhibitor, Clinical Sciences, Immunology
Abstract

Early phase studies of alvocidib showed activity in relapsed CLL including patients with high risk genomic features and those refractory to fludarabine. A multi-center, international, phase II study of alvocidib in fludarabine refractory CLL was undertaken to validate these early results. Patients with fludarabine refractory CLL or prolymphocytic leukemia arising from CLL were treated with single agent alvocidib. The primary outcome measure was overall response rate, with secondary outcomes including survival, toxicity, and response duration. One hundred and sixty five patients were enrolled and 159 patients were treated. The median age was 61 years, the median number of prior therapies was 4, and 96% of patients were fludarabine refractory. The investigator-assessed overall response rate was 25%; the majority of responses were partial. Response rates were lower among patients with del(17p) (14%), but equivalent in patients with del(11q) or bulky lymphadenopathy. Median progression free and overall survival were 7.6 and 14.6 months, respectively. Tumor lysis occurred in 39 patients (25%), and 13 received hemodialysis. Diarrhea, fatigue, and hematologic toxicities were common. Alvocidib has clinical activity in patients with advanced, fludarabine refractory CLL. Future studies should focus on discovery of biomarkers of clinical response and tumor lysis, and enhanced supportive care measures.

Published
2015

12. Immunoglobulin transcript sequence and somatic hypermutation computation from unselected RNA-seq reads in chronic lymphocytic leukemia

Author

Blachly, James S, Ruppert, Amy S, Zhao, Weiqiang, Long, Susan, Flynn, Joseph, Flinn, Ian, Jones, Jeffrey, Maddocks, Kami, Andritsos, Leslie, Ghia, Emanuela M, Rassenti, Laura Z, Kipps, Thomas J, de la Chapelle, Albert, and Byrd, John C

Subjects
Rare Diseases, Lymphoma, Genetics, Cancer, Hematology, Alleles, Base Sequence, Complementarity Determining Regions, Genome, Humans, Immunoglobulin Variable Region, Immunoglobulins, Leukemia, Lymphocytic, Chronic, B-Cell, Molecular Sequence Data, Polymerase Chain Reaction, Prognosis, Sequence Analysis, RNA, Sequence Homology, Nucleic Acid, Somatic Hypermutation, Immunoglobulin, Transcriptome, VDJ Recombinases, RNA sequencing, immunoglobulin, somatic hypermutation, B cells, CLL
Abstract

Immunoglobulins (Ig) are produced by B lymphocytes as secreted antibodies or as part of the B-cell receptor. There is tremendous diversity of potential Ig transcripts (>1 × 10(12)) as a result of hundreds of germ-line gene segments, random nucleotide incorporation during joining of gene segments into a complete transcript, and the process of somatic hypermutation at individual nucleotides. This recombination and mutation process takes place in the maturing B cell and is responsible for the diversity of potential epitope recognition. Cancers arising from mature B cells are characterized by clonal production of Ig heavy (IGH@) and light chain transcripts, although whether the sequence has undergone somatic hypermutation is dependent on the maturation stage at which the neoplastic clone arose. Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults and arises from a mature B cell with either mutated or unmutated IGH@ transcripts, the latter having worse prognosis and the assessment of which is routinely performed in the clinic. Currently, IGHV mutation status is assessed by Sanger sequencing and comparing the transcript to known germ-line genes. In this paper, we demonstrate that complete IGH@ V-D-J sequences can be computed from unselected RNA-seq reads with results equal or superior to the clinical procedure: in the only discordant case, the clinical transcript was out-of-frame. Therefore, a single RNA-seq assay can simultaneously yield gene expression profile, SNP and mutation information, as well as IGHV mutation status, and may one day be performed as a general test to capture multidimensional clinically relevant data in CLL.

Published
2015

13. BEAM or BUCYVP16-conditioning regimen for autologous stem-cell transplantation in non-Hodgkin’s lymphomas

Author

Singer, Sara, Sharma, Nidhi, Dean, Robert, Zhao, Qiuhong, Abounader, Donna, Elder, Patrick, Hofmeister, Craig C., Benson, Don M., Rosko, Ashley, Penza, Sam, Andritsos, Leslie, Vasu, Sumithira, Jaglowski, Samantha, William, Basem M., Bolwell, Brian, Pohlman, Brad, Kalaycio, Matt, Jagadeesh, Deepa, Hill, Brian, Sobecks, Ronald, Devine, Steven M., Majhail, Navneet S., and Efebera, Yvonne A.

Published
2019
Full Text
View/download PDF

14. BEAM versus BUCYVP16 Conditioning before Autologous Hematopoietic Stem Cell Transplant in Patients with Hodgkin Lymphoma

Author

Singer, Sara, Dean, Robert, Zhao, Qiuhong, Sharma, Nidhi, Abounader, Donna, Elder, Patrick, Hofmeister, Craig C., Benson, Don M., Rosko, Ashley, Penza, Sam, Andritsos, Leslie, Vasu, Sumithira, Jaglowski, Samantha, William, Basem M., Bolwell, Brian, Pohlman, Brad, Kalaycio, Matt, Jagadeesh, Deepa, Hill, Brian, Sobecks, Ronald, Devine, Steven M., Majhail, Navneet S., and Efebera, Yvonne A.

Published
2019
Full Text
View/download PDF

15. Hairy cell leukemia variant and WHO classification correspondence Re: 5thedition WHO classification haematolymphoid tumors: lymphoid neoplasms

Author

Grever, Michael, Andritsos, Leslie, Anghelina, Mirela, Arons, Evgeny, Banerji, Versha, Barrientos, Jacqueline, Bhat, Seema A., Blachly, James, Broccoli, Alessandro, Call, Timothy, Dearden, Claire, Dietrich, Sascha, Else, Monica, Epperla, Narendranath, Fagarasanu, Andrei, Falini, Brunangelo, Forconi, Francesco, Gozzetti, Alessandro, Hampel, Paul, Hermel, David J., Iyengar, Sunil, Johnston, James B., Juliusson, Gunnar, Kreitman, Robert J., Lauria, Francesco, Lozanski, Gerard, Oakes, Christopher C., Parikh, Sameer A., Park, Jae, Quest, Graeme, Rai, Kanti, Ravandi, Farhad, Robak, Tadeusz, Rogers, Kerry A., Saven, Alan, Seymour, John F., Tadmor, Tamar, Tallman, Martin S., Tam, Constantine S., Tiacci, Enrico, Troussard, Xavier, Wörmann, Bernhard, Zent, Clive S., Zenz, Thorsten, and Zinzani, Pier Luigi

Published
2024
Full Text
View/download PDF

17. Data from The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation

Author

Reiff, Sean D., primary, Mantel, Rose, primary, Smith, Lisa L., primary, Greene, J.T., primary, Muhowski, Elizabeth M., primary, Fabian, Catherine A., primary, Goettl, Virginia M., primary, Tran, Minh, primary, Harrington, Bonnie K., primary, Rogers, Kerry A., primary, Awan, Farrukh T., primary, Maddocks, Kami, primary, Andritsos, Leslie, primary, Lehman, Amy M., primary, Sampath, Deepa, primary, Lapalombella, Rosa, primary, Eathiraj, Sudharshan, primary, Abbadessa, Giovanni, primary, Schwartz, Brian, primary, Johnson, Amy J., primary, Byrd, John C., primary, and Woyach, Jennifer A., primary

Published
2023
Full Text
View/download PDF

18. Suppl Table 2 from The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation

Author

Reiff, Sean D., primary, Mantel, Rose, primary, Smith, Lisa L., primary, Greene, J.T., primary, Muhowski, Elizabeth M., primary, Fabian, Catherine A., primary, Goettl, Virginia M., primary, Tran, Minh, primary, Harrington, Bonnie K., primary, Rogers, Kerry A., primary, Awan, Farrukh T., primary, Maddocks, Kami, primary, Andritsos, Leslie, primary, Lehman, Amy M., primary, Sampath, Deepa, primary, Lapalombella, Rosa, primary, Eathiraj, Sudharshan, primary, Abbadessa, Giovanni, primary, Schwartz, Brian, primary, Johnson, Amy J., primary, Byrd, John C., primary, and Woyach, Jennifer A., primary

Published
2023
Full Text
View/download PDF

19. Suppl Figure 1 from The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation

Author

Reiff, Sean D., primary, Mantel, Rose, primary, Smith, Lisa L., primary, Greene, J.T., primary, Muhowski, Elizabeth M., primary, Fabian, Catherine A., primary, Goettl, Virginia M., primary, Tran, Minh, primary, Harrington, Bonnie K., primary, Rogers, Kerry A., primary, Awan, Farrukh T., primary, Maddocks, Kami, primary, Andritsos, Leslie, primary, Lehman, Amy M., primary, Sampath, Deepa, primary, Lapalombella, Rosa, primary, Eathiraj, Sudharshan, primary, Abbadessa, Giovanni, primary, Schwartz, Brian, primary, Johnson, Amy J., primary, Byrd, John C., primary, and Woyach, Jennifer A., primary

Published
2023
Full Text
View/download PDF

20. Supplemental Methods from The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation

Author

Reiff, Sean D., primary, Mantel, Rose, primary, Smith, Lisa L., primary, Greene, J.T., primary, Muhowski, Elizabeth M., primary, Fabian, Catherine A., primary, Goettl, Virginia M., primary, Tran, Minh, primary, Harrington, Bonnie K., primary, Rogers, Kerry A., primary, Awan, Farrukh T., primary, Maddocks, Kami, primary, Andritsos, Leslie, primary, Lehman, Amy M., primary, Sampath, Deepa, primary, Lapalombella, Rosa, primary, Eathiraj, Sudharshan, primary, Abbadessa, Giovanni, primary, Schwartz, Brian, primary, Johnson, Amy J., primary, Byrd, John C., primary, and Woyach, Jennifer A., primary

Published
2023
Full Text
View/download PDF

21. Suppl Table 1 from The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation

Author

Reiff, Sean D., primary, Mantel, Rose, primary, Smith, Lisa L., primary, Greene, J.T., primary, Muhowski, Elizabeth M., primary, Fabian, Catherine A., primary, Goettl, Virginia M., primary, Tran, Minh, primary, Harrington, Bonnie K., primary, Rogers, Kerry A., primary, Awan, Farrukh T., primary, Maddocks, Kami, primary, Andritsos, Leslie, primary, Lehman, Amy M., primary, Sampath, Deepa, primary, Lapalombella, Rosa, primary, Eathiraj, Sudharshan, primary, Abbadessa, Giovanni, primary, Schwartz, Brian, primary, Johnson, Amy J., primary, Byrd, John C., primary, and Woyach, Jennifer A., primary

Published
2023
Full Text
View/download PDF

22. Suppl Figure 2 from The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation

Author

Reiff, Sean D., primary, Mantel, Rose, primary, Smith, Lisa L., primary, Greene, J.T., primary, Muhowski, Elizabeth M., primary, Fabian, Catherine A., primary, Goettl, Virginia M., primary, Tran, Minh, primary, Harrington, Bonnie K., primary, Rogers, Kerry A., primary, Awan, Farrukh T., primary, Maddocks, Kami, primary, Andritsos, Leslie, primary, Lehman, Amy M., primary, Sampath, Deepa, primary, Lapalombella, Rosa, primary, Eathiraj, Sudharshan, primary, Abbadessa, Giovanni, primary, Schwartz, Brian, primary, Johnson, Amy J., primary, Byrd, John C., primary, and Woyach, Jennifer A., primary

Published
2023
Full Text
View/download PDF

23. PD-1 blockade for relapsed lymphoma post–allogeneic hematopoietic cell transplant: high response rate but frequent GVHD

Author

Haverkos, Bradley M., Abbott, Diana, Hamadani, Mehdi, Armand, Philippe, Flowers, Mary E., Merryman, Reid, Kamdar, Manali, Kanate, Abraham Sebastian, Saad, Ayman, Mehta, Amitkumar, Ganguly, Siddhartha, Fenske, Timothy S., Hari, Parameswaran, Lowsky, Robert, Andritsos, Leslie, Jagasia, Madan, Bashey, Asad, Brown, Stacey, Bachanova, Veronika, Stephens, Deborah, Mineishi, Shin, Nakamura, Ryotaro, Chen, Yi-Bin, Blazar, Bruce R., Gutman, Jonathan, and Devine, Steven M.

Published
2017
Full Text
View/download PDF

24. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia

Author

Grever, Michael R., Abdel-Wahab, Omar, Andritsos, Leslie A., Banerji, Versha, Barrientos, Jacqueline, Blachly, James S., Call, Timothy G., Catovsky, Daniel, Dearden, Claire, Demeter, Judit, Else, Monica, Forconi, Francesco, Gozzetti, Alessandro, Ho, Anthony D., Johnston, James B., Jones, Jeffrey, Juliusson, Gunnar, Kraut, Eric, Kreitman, Robert J., Larratt, Loree, Lauria, Francesco, Lozanski, Gerard, Montserrat, Emili, Parikh, Sameer A., Park, Jae H., Polliack, Aaron, Quest, Graeme R., Rai, Kanti R., Ravandi, Farhad, Robak, Tadeusz, Saven, Alan, Seymour, John F., Tadmor, Tamar, Tallman, Martin S., Tam, Constantine, Tiacci, Enrico, Troussard, Xavier, Zent, Clive S., Zenz, Thorsten, Zinzani, Pier Luigi, and Falini, Brunangelo

Published
2017
Full Text
View/download PDF

26. Data from Early Intervention with Lenalidomide in Patients with High-risk Chronic Lymphocytic Leukemia

Author

Thangavadivel, Shanmugapriya, primary, Zhao, Qiuhong, primary, Epperla, Narendranath, primary, Rike, Lindsey, primary, Mo, Xiaokui, primary, Badawi, Mohamed, primary, Bystry, Darlene M., primary, Phelps, Mitch A., primary, Andritsos, Leslie A., primary, Rogers, Kerry A., primary, Jones, Jeffrey, primary, Woyach, Jennifer A., primary, Byrd, John C., primary, and Awan, Farrukh T., primary

Published
2023
Full Text
View/download PDF

27. Supplementary Data from Early Intervention with Lenalidomide in Patients with High-risk Chronic Lymphocytic Leukemia

Author

Thangavadivel, Shanmugapriya, primary, Zhao, Qiuhong, primary, Epperla, Narendranath, primary, Rike, Lindsey, primary, Mo, Xiaokui, primary, Badawi, Mohamed, primary, Bystry, Darlene M., primary, Phelps, Mitch A., primary, Andritsos, Leslie A., primary, Rogers, Kerry A., primary, Jones, Jeffrey, primary, Woyach, Jennifer A., primary, Byrd, John C., primary, and Awan, Farrukh T., primary

Published
2023
Full Text
View/download PDF

28. Impact of sex on outcomes in patients with hairy cell leukemia. An HCL patient data registry analysis

Author

Epperla, Narendranath, primary, Zhao, Qiuhong, additional, Anghelina, Mirela, additional, Neal, Jasmine, additional, Blachly, James S., additional, Rogers, Kerry A., additional, Lozanski, Gerard, additional, Oakes, Christopher C., additional, Bhat, Seema A., additional, Zent, Clive S., additional, Banerji, Versha, additional, Grever, Michael, additional, and Andritsos, Leslie A., additional

Published
2023
Full Text
View/download PDF

29. Granulocyte Colony-Stimulating Factor–Mobilized Allografts Contain Activated Immune Cell Subsets Associated with Risk of Acute and Chronic Graft-versus-Host Disease

Author

Vasu, Sumithira, Geyer, Susan, Bingman, Anissa, Auletta, Jeffery J., Jaglowski, Samantha, Elder, Pat, Donnell, Lynn O., Bradbury, Hillary, Kitzler, Rhonda, Andritsos, Leslie, Blum, William, Klisovic, Rebecca, Penza, Sam, Efebera, Yvonne, Hofmeister, Craig, Benson, Don M., Muthusamy, Natarajan, Lozanski, Gerard, and Devine, Steven M.

Published
2016
Full Text
View/download PDF

30. Atorvastatin for the Prophylaxis of Acute Graft-versus-Host Disease in Patients Undergoing HLA-Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT)

Author

Efebera, Yvonne A., Geyer, Susan, Andritsos, Leslie, Vasu, Sumithira, Jaglowski, Samantha, Bingman, Anissa, Blum, William, Klisovic, Rebecca, Hofmeister, Craig C., Benson, Don M., Penza, Sam, Elder, Patrick, Cortright, Katie, Kitzler, Rhonda, Coombes, Kevin, O'Donnell, Lynn, Daneault, Beth, Bradbury, Hillary, Zhang, Jianying, Chen, Xilin, Garman, Sabrina, Ranganathan, Parvathi, Yu, Xueyan, Hofstetter, Jessica, Yu, Jianhua, Garzon, Ramiro, Scrape, Scott R., Lozanski, Gerard, and Devine, Steven M.

Published
2016
Full Text
View/download PDF

32. Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study

Author

Jaglowski, Samantha M., Jones, Jeffrey A., Nagar, Veena, Flynn, Joseph M., Andritsos, Leslie A., Maddocks, Kami J., Woyach, Jennifer A., Blum, Kristie A., Grever, Michael R., Smucker, Kelly, Ruppert, Amy S., Heerema, Nyla A., Lozanski, Gerard, Stefanos, Mona, Munneke, Brian, West, Jamie-Sue, Neuenburg, Jutta K., James, Danelle F., Hall, Nathan, Johnson, Amy J., and Byrd, John C.

Published
2015
Full Text
View/download PDF

33. Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation

Author

Liu, Ta-Ming, Woyach, Jennifer A., Zhong, Yiming, Lozanski, Arletta, Lozanski, Gerard, Dong, Shuai, Strattan, Ethan, Lehman, Amy, Zhang, Xiaoli, Jones, Jeffrey A., Flynn, Joseph, Andritsos, Leslie A., Maddocks, Kami, Jaglowski, Samantha M., Blum, Kristie A., Byrd, John C., Dubovsky, Jason A., and Johnson, Amy J.

Published
2015
Full Text
View/download PDF

36. Retrospective Analysis of Residual Hairy Cell Leukemia Measured By IHC or Flow Cytometry and Frontline Treatment with Pentostatin on Time to Next Treatment

Author

Stiff, Andrew, primary, Zhao, Qiuhong, additional, Kapoor, Nilesh, additional, Rogers, Kerry A., additional, Anghelina, Mirela Iulia, additional, Neal, Jasmine, additional, Andritsos, Leslie A., additional, Blachly, James S., additional, Lozanski, Gerard, additional, Grever, Michael R., additional, and Bhat, Seema A., additional

Published
2022
Full Text
View/download PDF

37. Incidence, Description, and Timing of Serious or Opportunistic Infections in Patients with Hairy Cell Leukemia Treated with Purine Nucleoside Analogues

Author

Kapoor, Nilesh, primary, Zhao, Qiuhong, additional, Stiff, Andrew, additional, Bhat, Seema A., additional, Anghelina, Mirela Iulia, additional, Neal, Jasmine, additional, Andritsos, Leslie A., additional, Blachly, James S., additional, Epperla, Narendranath, additional, El Boghdadly, Zeinab, additional, Grever, Michael R., additional, and Rogers, Kerry A., additional

Published
2022
Full Text
View/download PDF

38. Extended Follow up of a Phase 2 Study of Ibrutinib in Hairy Cell Leukemia

Author

Rogers, Kerry A., primary, McLaughlin, Eric, additional, Wei, Lai, additional, Anghelina, Mirela Iulia, additional, Ali, Mir Khader, additional, Andritsos, Leslie A., additional, Arons, Evgeny, additional, Blachly, James S., additional, Call, Timothy G., additional, Ivy, S. Percy, additional, James-Echenique, Lacey, additional, Jones, Jeffrey A., additional, Kreitman, Robert J., additional, Lozanski, Gerard, additional, Ravandi, Farhad, additional, Schiffer, Charles A., additional, Carson, William E., additional, and Grever, Michael R., additional

Published
2022
Full Text
View/download PDF

39. Ibrutinib treatment improves T cell number and function in CLL patients

Author

Long, Meixiao, Beckwith, Kyle, Do, Priscilla, Mundy, Bethany L., Gordon, Amber, Lehman, Amy M., Maddocks, Kami J., Cheney, Carolyn, Jones, Jeffrey A., Flynn, Joseph M., Andritsos, Leslie A., Awan, Farrukh, Fraietta, Joseph A., June, Carl H., Maus, Marcela V., Woyach, Jennifer A., Caligiuri, Michael A., Johnson, Amy J., Muthusamy, Natarajan, and Byrd, John C.

Subjects
Ibrutinib -- Dosage and administration, Chronic lymphocytic leukemia -- Drug therapy -- Research, Treatment outcome -- Analysis, T cells -- Research, Health care industry
Abstract

BACKGROUND. Ibrutinib has been shown to have immunomodulatory effects by inhibiting Bruton's tyrosine kinase (BTK) and IL-2-inducible T cell kinase (ITK). The relative importance of inhibiting these 2 kinases has not been examined despite its relevance to immune-based therapies. METHODS. Peripheral blood mononuclear cells from chronic lymphocytic leukemia (CLL) patients on clinical trials of ibrutinib (BTK/ITK inhibitor; n = 19) or acalabrutinib (selective BTK inhibitor; n = 13) were collected serially. T cell phenotype, immune function, and CLL cell immunosuppressive capacity were evaluated. RESULTS. Ibrutinib markedly increased [CD4.sup.+] and [CD8.sup.+] T cell numbers in CLL patients. This effect was more prominent in effector/effector memory subsets and was not observed with acalabrutinib. Ex vivo studies demonstrated that this may be due to diminished activation-induced cell death through ITK inhibition. PD-1 and CTLA-4 expression was significantly markedly reduced in T cells by both agents. While the number of Treg cells remained unchanged, the ratio of these to conventional [CD4.sup.+] T cells was reduced with ibrutinib, but not acalabrutinib. Both agents reduced expression of the immunosuppressive molecules CD200 and BTLA as well as IL-10 production by CLL cells. CONCLUSIONS. Ibrutinib treatment increased the in vivo persistence of activated T cells, decreased the Treg/ [CD4.sup.+] T cell ratio, and diminished the immune-suppressive properties of CLL cells through BTK-dependent and -independent mechanisms. These features provide a strong rationale for combination immunotherapy approaches with ibrutinib in CLL and other cancers. TRIAL REGISTRATION. ClinicalTrials.gov NCT01589302 and NCT02029443. Samples described here were collected per OSU-0025. FUNDING. The National Cancer Institute., Introduction Chronic lymphocytic leukemia (CLL) patients are characterized by a profound immune suppression and perturbation of both innate as well as adaptive immunity (1), highlighted by increased susceptibility to infections, [...]

Published
2017
Full Text
View/download PDF

40. Corrigendum to “Patient-driven research: Initial results from a prospective health–related quality of life study performed at the request of patients living with hairy cell leukemia” [Leuk. Res. 120 (2022) 106919]

Author

Anghelina, Mirela, primary, Naughton, Michelle J., additional, Zhao, Qiuhong, additional, Ruppert, Amy S., additional, Neal, Jasmine, additional, Rogers, Kerry A., additional, Blachly, James S., additional, Lozanski, Gerard, additional, Bhat, Seema A., additional, Kraut, Eric, additional, Epperla, Narendranath, additional, Mathur, Puneet, additional, Zent, Clive S., additional, Banerji, Versha, additional, Dearden, Claire, additional, Hutchinson, Terri, additional, Grever, Michael, additional, and Andritsos, Leslie A., additional

Published
2022
Full Text
View/download PDF

41. Development of a distributed international patient data registry for hairy cell leukemia

Author

Andritsos, Leslie A., primary, Anghelina, Mirela, additional, Neal, Jasmine, additional, Blachly, James S., additional, Mathur, Puneet, additional, Lele, Omkar, additional, Dearden, Claire, additional, Iyengar, Sunil, additional, Cross, Matthew, additional, Zent, Clive S., additional, Rogers, Kerry A., additional, Epperla, Narendranath, additional, Lozanski, Gerard, additional, Oakes, Christopher C., additional, Kraut, Eric, additional, Ruppert, Amy S., additional, Zhao, Qiuhong, additional, Bhat, Seema A., additional, Forconi, Francesco, additional, Banerji, Versha, additional, Handunnetti, Sasanka, additional, Tam, Constantine S., additional, Seymour, John F., additional, Else, Monica, additional, Kreitman, Robert J., additional, Saven, Alan, additional, Call, Timothy, additional, Parikh, Sameer A., additional, Ravandi, Farhad, additional, Johnston, James B., additional, Tiacci, Enrico, additional, Troussard, Xavier, additional, Tallman, Martin S., additional, Dietrich, Sascha, additional, Tadmor, Tamar, additional, Gozzetti, Alessandro, additional, Zinzani, Pier Luigi, additional, Robak, Tadeusz, additional, Quest, Graeme, additional, Demeter, Judit, additional, Rai, Kanti, additional, Fernandez, Soledad A., additional, and Grever, Michael, additional

Published
2022
Full Text
View/download PDF

49. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes

Author

Dubovsky, Jason A., Beckwith, Kyle A., Natarajan, Gayathri, Woyach, Jennifer A., Jaglowski, Samantha, Zhong, Yiming, Hessler, Joshua D., Liu, Ta-Ming, Chang, Betty Y., Larkin, Karilyn M., Stefanovski, Matthew R., Chappell, Danielle L., Frissora, Frank W., Smith, Lisa L., Smucker, Kelly A., Flynn, Joseph M., Jones, Jeffrey A., Andritsos, Leslie A., Maddocks, Kami, Lehman, Amy M., Furman, Richard, Sharman, Jeff, Mishra, Anjali, Caligiuri, Michael A., Satoskar, Abhay R., Buggy, Joseph J., Muthusamy, Natarajan, Johnson, Amy J., and Byrd, John C.

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results